These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11893198)

  • 1. Asymmetric total synthesis of (+)-fostriecin.
    Reddy YK; Falck JR
    Org Lett; 2002 Mar; 4(6):969-71. PubMed ID: 11893198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Versatile enantiocontrolled synthesis of (+)-fostriecin.
    Esumi T; Okamoto N; Hatakeyama S
    Chem Commun (Camb); 2002 Dec; (24):3042-3. PubMed ID: 12536807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.
    Maki K; Motoki R; Fujii K; Kanai M; Kobayashi T; Tamura S; Shibasaki M
    J Am Chem Soc; 2005 Dec; 127(48):17111-7. PubMed ID: 16316259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition.
    Buck SB; Hardouin C; Ichikawa S; Soenen DR; Gauss CM; Hwang I; Swingle MR; Bonness KM; Honkanen RE; Boger DL
    J Am Chem Soc; 2003 Dec; 125(51):15694-5. PubMed ID: 14677930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
    Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
    J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of the C1-C12 fragment of fostriecin.
    Cossy J; Pradaux F; BouzBouz S
    Org Lett; 2001 Jul; 3(14):2233-5. PubMed ID: 11440587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fostriecin: chemistry and biology.
    Lewy DS; Gauss CM; Soenen DR; Boger DL
    Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
    Lawhorn BG; Boga SB; Wolkenberg SE; Colby DA; Gauss CM; Swingle MR; Amable L; Honkanen RE; Boger DL
    J Am Chem Soc; 2006 Dec; 128(51):16720-32. PubMed ID: 17177422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total synthesis of fostriecin (CI-920) via a convergent route.
    Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
    Chem Commun (Camb); 2002 Apr; (7):742-3. PubMed ID: 12119701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.
    Bialy L; Waldmann H
    Chemistry; 2004 Jun; 10(11):2759-80. PubMed ID: 15195307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantio- and stereoselective route to the phoslactomycin family of antibiotics: formal synthesis of (+)-fostriecin and (+)-phoslactomycin B.
    Sarkar SM; Wanzala EN; Shibahara S; Takahashi K; Ishihara J; Hatakeyama S
    Chem Commun (Camb); 2009 Oct; (39):5907-9. PubMed ID: 19787137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formal total synthesis of fostriecin.
    Wang YG; Kobayashi Y
    Org Lett; 2002 Dec; 4(26):4615-8. PubMed ID: 12489943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
    McCluskey A; Sim AT; Sakoff JA
    J Med Chem; 2002 Mar; 45(6):1151-75. PubMed ID: 11881984
    [No Abstract]   [Full Text] [Related]  

  • 14. Total synthesis of fostriecin: via a regio- and stereoselective polyene hydration, oxidation, and hydroboration sequence.
    Gao D; O'Doherty GA
    Org Lett; 2010 Sep; 12(17):3752-5. PubMed ID: 20687585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.
    Weinbrenner C; Baines CP; Liu GS; Armstrong SC; Ganote CE; Walsh AH; Honkanen RE; Cohen MV; Downey JM
    Circulation; 1998 Sep; 98(9):899-905. PubMed ID: 9738645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total synthesis of an antitumor antibiotic, Fostriecin (CI-920).
    Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
    J Am Chem Soc; 2003 Jul; 125(27):8238-43. PubMed ID: 12837094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinuclear asymmetric Zn aldol additions: formal asymmetric synthesis of fostriecin.
    Trost BM; Frederiksen MU; Papillon JP; Harrington PE; Shin S; Shireman BT
    J Am Chem Soc; 2005 Mar; 127(11):3666-7. PubMed ID: 15771479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predicted beta12-beta13 loop is important for inhibition of PP2Acalpha by the antitumor drug fostriecin.
    Evans DR; Simon JA
    FEBS Lett; 2001 Jun; 498(1):110-5. PubMed ID: 11389908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of fostriecin (CI-920).
    Boger DL; Ichikawa S; Zhong W
    J Am Chem Soc; 2001 May; 123(18):4161-7. PubMed ID: 11457179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.
    Hastie CJ; Cohen PT
    FEBS Lett; 1998 Jul; 431(3):357-61. PubMed ID: 9714542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.